Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
This article was originally published on MedicalXpress.com